Innovate UK Project Enhances Automation in Cell and Gene Therapy Manufacturing
The CGT Catapult leads a collaborative project with multiple partners to develop an automation roadmap for scalable manufacturing in cell and gene therapies. This initiative aims to reduce costs and increase throughput, ultimately enhancing patient access to these advanced therapies.
Theia Market Signal Identification - AI Assisted
The Cell and Gene Therapy Catapult (CGT Catapult) is spearheading a project funded by Innovate UK in partnership with Cellular Origins, Resolution Therapeutics, Autolomous, and ScaleReady. This initiative focuses on integrating robotic systems into cell therapy manufacturing to improve scalability and efficiency.
The project includes using Cellular Origins' ConstellationTM platform alongside ScaleReady's facilities, aiming to decrease manual processes while ensuring compliance with GMP standards. Future steps include completing CAR-T proof-of-concept runs and analyzing data to establish the feasibility of automation in enhancing manufacturing processes. Effective collaboration among diverse partners highlights the critical nature of aligning objectives and expectations, which is essential for advancing the project.
Comments